The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...
March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...
Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...
Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...
When you’re living with bronchiectasis, your primary goal in managing the condition is to reduce “exacerbations” — episodes in which you’re coughing, breathless, and making more phlegm — and to ...
Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results